40 completed, 11 terminated, 10 recruiting, 8 withdrawn. 15 Phase 2, 14 Phase 1, 14 Phase 3, 13 Not applicable, 7 Early Phase 1.
Follow Ferumoxytol: new trials by email Literature Review of Ferumoxytol trials Research Report on Ferumoxytol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nanozymes in Endodontics Nanozyme treatment, Control (Standard treatment) - Apical Periodontitis, Endodontic Disease | Phase 4 | Enrolling by invitation | University of Pennsylvania | 72 | 2026-08-24 | 2026-10-13 |
| Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients Biospecimen Collection, Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Diffusion-Relaxation Correlation Spectrum Imaging - Glioblastoma | Phase 3 | Recruiting | Jonsson Comprehensive Cancer Center | 15 | 2025-10-27 | 2026-03-10 |
| Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy Ferumoxytol - Epilepsy, Temporal Lobe | Phase 2 | Recruiting | University of Alberta | 50 | 2025-05-01 | 2026-05-08 |
| Calculating Wall Shear Stress in Infant Pulmonary Veins Ferumoxytol - Pulmonary Vein Stenosis | Phase 1 | Recruiting | Children's Hospital of Philadelphia | 20 | 2024-09-30 | 2026-08-05 |
| A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries Superparamagnetic Iron Oxide Nanoparticles - Coronary Artery Calcification | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 100 | 2024-01-26 | 2026-02-10 | |
| A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus Superparamagnetic Iron Oxide Nanoparticles - Heart Aneurysm | Unknown | The First Affiliated Hospital with Nanjing Medical University | 320 | 2023-11-06 | 2024-09-23 | |
| Phenotyping Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) by Intravesical Contrast Enhanced - Magnetic Resonance Imaging (ICE-MRI) Bladder Permeability Assay Ferumoxytol, Gadobutrol - IC - Interstitial Cystitis | Completed | Christopher J Chermansky, MD | 7 | 2023-03-29 | 2026-07-10 | |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Bryan Allen | 16 | 2023-02-28 | 2026-07-20 |
| Early Antenatal Support for Iron Deficiency Anemia Ferumoxytol, Ferrous Sulfate - Pregnancy Related, Anemia, Iron Deficiency | Phase 4 | Recruiting | Thomas Jefferson University | 80 | 2021-09-29 | 2025-12-02 |
| Assessment of Renal Vasculature and Function with Ferumoxytol-enhanced Magnetic Resonance Imaging domestic polysaccharide superparamagnetic iron oxide nanoparticle - Chronic Kidney Diseases | Phase 1 | Completed | The First Affiliated Hospital with Nanjing Medical University | 44 | 2021-09-17 | 2024-09-25 |
| Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient Ferumoxytol, Saline, Ferrous sulfate tablets - Iron Deficiency Anemia | Phase 3 | Recruiting | Auerbach Hematology Oncology Associates P C | 104 | 2020-02-27 | 2025-10-03 |
| IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding Ferumoxytol, Ferrous Sulfate - Anemia, Iron Deficiency, Heavy Menstrual Bleeding | Phase 4 | Unknown | Thomas Jefferson University | 76 | 2020-02-14 | 2023-11-21 |
| A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects ferumoxytol, Iron sucrose - Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 75 | 2019-09-18 | 2026-04-17 |
| Intravenous (IV) Versus Oral Iron Treatment of Iron Deficiency Anemia in the Post-operative Bariatric Surgical Patient Ferumoxytol, Ferrous sulfate, Oral vitamin C - IDA in the Post-bariatric Surgical Patient | Not applicable | Withdrawn | Johns Hopkins University | 2019-08-01 | 2019-09-11 | |
| Feasibility of FMISO in Brain Tumors ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging - IDH Wild Type Glioblastoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 77 | 2019-06-01 | 2026-09-18 |
| Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy Ferrous sulfate 325mg, Ferumoxytol - Iron Deficiency Anemia of Pregnancy | Phase 3 | Completed | University of Arizona | 124 | 2018-12-17 | 2022-09-07 |
| Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Ferumoxytol - Pulmonary Embolism | Phase 1 | Completed | Brigham and Women's Hospital | 1 | 2018-09-21 | 2022-07-26 |
| A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) Ferumoxytol, Iron sucrose - Chronic Kidney Disease; Iron Deficiency Anemia | Phase 3 | Recruiting | AMAG Pharmaceuticals, Inc. | 129 | 2018-08-13 | 2026-04-17 |
| Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer Ferumoxytol, Magnetic Resonance Imaging - Stage IIB Esophageal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7 | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2018-04-27 | 2021-09-16 | |
| Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol - Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7 | Early Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2018-04-27 | 2021-09-10 |
Showing 20 of 75. Sign in to see all of them.
Anemia, Iron-Deficiency (17) · Brain Neoplasms (6) · Renal Insufficiency, Chronic (6) · Glioblastoma (5) · Anemia (4) · Esophageal Neoplasms (3) · Prostatic Neoplasms (3) · AIDS Dementia Complex (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Inflammation (2) · Multiple Sclerosis (2) · Bone Neoplasms (1) · Brain Injuries (1) · Breast Neoplasms (1)
OHSU Knight Cancer Institute (14) · AMAG Pharmaceuticals, Inc. (13) · National Cancer Institute (NCI) (3) · Stanford University (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Auerbach Hematology Oncology Associates P C (2) · Brigham and Women's Hospital (2) · Dana-Farber Cancer Institute (2) · Massachusetts General Hospital (2) · Michael Iv (2) · Thomas Jefferson University (2) · University of Edinburgh (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Beau Nakamoto (1) · Bryan Allen (1)
United States (59) · Canada (8) · Poland (7) · Hungary (5) · United Kingdom (5) · Latvia (4) · Lithuania (4) · China (3) · India (3) · Germany (2) · Australia (1) · Belgium (1) · Denmark (1) · France (1) · Italy (1)
Edward Neuwelt (4) · Alexander Guimaraes (3) · Edward A Neuwelt (2) · Edward A Neuwelt, MD (2) · Allison O'Neill, MD (1) · Andrew M Siedlecki, MD (1) · Beau K Nakamoto, MD, PhD (1) · Beau Nakamoto, MD, PhD (1) · Brian Rutt, PhD (1) · Christopher Chermansky, MD (1) · Chunjian Li, Dr,PhD (1) · Chunjian Li, MD, PhD (1) · Chunjian Li, Phd、MD (1) · Clifton Fuller, MD (1) · Colin Stirrat, MBChB (1)
PMID 18084623, PMID 22875883, PMID 23828252, PMID 24458078, PMID 24559803, PMID 26786296, PMID 27465647, PMID 28372549, PMID 28642288, PMID 28986407, PMID 29248659, PMID 30518682, PMID 30802204, PMID 31104505, PMID 31673393, PMID 32368961, PMID 33201358, PMID 34870211, PMID 36734848, PMID 36999999, PMID 37010988, PMID 37348816, PMID 37348817
R01CA137488 (3), 2009 (1), K08CA237809 (1), K08EB012859 (1), KL2TR001882 (1), P01AI054904 (1), P30CA069533 (1), P30CA124435 (1), R01CA269231 (1), R01NS034608 (1), R21CA270742 (1), R21NS087951 (1), R37CA288577 (1), R44DK108397 (1), U01CA278923 (1)